Clinical Trials


Romark is among the many companies working to respond to the novel coronavirus global health emergency. Romark has on-going clinical studies of its investigational new drug candidate NT-300 (nitazoxanide extended-release) for both the prevention and treatment of COVID-19 and other viral respiratory illnesses. See below for more information.
Romark completed its clinical trial of NT-300 (nitazoxanide extended-release) in the treatment of mild or moderate COVID-19.


Information about the trial is available at the following link:
Romark also has on-going Phase 3 clinical trials of NT-300 (nitazoxanide extended-release tablets) for the prevention of COVID-19 and the treatment of viral respiratory illnesses caused by rhinoviruses and other enteroviruses.
Information about the trials is available at the following links:
To get involved, email: or call 877-925-4642.

NT-300 is an investigational new drug product and has not been approved by the U.S. Food and Drug Administration or other regulatory authorities for any use. The safety and efficacy of this new product has not been established.